Bluesight, an Alexandria, VA-based medication intelligence company, received a strategic growth investment from Thoma Bravo.
The amount of the deal was not disclosed. Current investor New Leaf Ventures will remain invested in the business.
The company intends to use the funds to further enhance its drug diversion prevention offerings through its acquisition of Medacist, and continue to grow its inventory management and spend optimization offerings.
Led by CEO Kevin MacDonald, Bluesight solves supply chain inefficiencies and reduces risk by using AI and machine learning to surface actionable analytics for every step of the medication lifecycle. Through its suite of Medication Intelligence™ solutions, the company brings visibility, and predictability to the complex medication management. Today, the company supports health systems with automated RFID-enabled kit and tray management through KitCheck™, controlled substance diversion management through ControlCheck™ and drug purchasing optimization through CostCheck™. More than 1,000 U.S. and Canadian hospitals utilize its solutions to optimize their hospital’s pharmacy practices by improving efficiency, reducing medication costs, and increasing compliance and safety.
The acquisition of Medacist combines two innovators in drug diversion analytics and medication management solutions that together will serve more than 2,000 hospitals across North America. Its advanced auditing capabilities and visibility across all hospital care areas complements Medacist’s streamlined reporting and visibility tools across the health system. Healthcare organizations will have a single source of software solutions that provides insights into medication usage and diversion to allow for the most accurate predictions, targeted interventions and, ultimately, improved patient outcomes.
FinSMEs
18/07/2023